Sophiris Bio, Inc.
SPHS
SPHS was delisted on the 11th of March, 2020.
30 hedge funds and large institutions have $6.45M invested in Sophiris Bio, Inc. in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 6 closing their positions.
88% more capital invested
Capital invested by funds: $3.43M → $6.45M (+$3.02M)
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
40% more call options, than puts
Call options by funds: $500K | Put options by funds: $356K
12% less funds holding
Funds holding: 34 → 30 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.38M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$573K |
| 3 |
JP Morgan Chase
New York
|
+$261K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$179K |
| 5 |
BO
BRR OpCo
Columbus,
Ohio
|
+$119K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$210K |
| 2 |
Goldman Sachs
New York
|
-$161K |
| 3 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$76K |
| 4 |
VF
Virtu Financial
New York
|
-$68K |
| 5 |
Bank of New York Mellon
New York
|
-$37.8K |
SPHS Hedge Fund Activity: Q2 2018 in Review
30 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q2 2018, worth a combined $6.45M — up 88% from $3.43M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SPHS and 2 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $1.38M. The largest seller was Millennium Management, exiting entirely with an estimated $210K sold.
- 30 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q2 2018, down from 34 in Q1 2018.
- Funds reported $6.45M of Sophiris Bio, Inc. stock for Q2 2018, up 88% quarter-over-quarter.
- 2 funds opened new Sophiris Bio, Inc. positions in Q2 2018 and 6 closed out, a net change of -4 holders.
- The largest Sophiris Bio, Inc. buyer in Q2 2018 was Vanguard Group, an estimated $1.38M added.
- The largest Sophiris Bio, Inc. seller in Q2 2018 was Millennium Management, an estimated $210K sold.
Based on aggregated 13F filings for Q2 2018.